We are searching data for your request:
Upon completion, a link will appear to access the found materials.
Girls have an additional vaccine that boys do not have on their official vaccination schedule: the Human Papillomavirus (HPV) vaccine, a virus that is responsible for cervical cancer.
Only in the European Union (EU) is cervical cancer the second most common in women after breast cancer. Each year there are around 33,000 new cases and 15,000 deaths from this type of tumor.
Additionally, a WHO study considers cervical cancer and other HPV-related diseases to be a global health problem. For this reason, WHO recommends that the routine vaccination of girls against this virus be included in national immunization programs. Girls 10-14 years old are the ideal age range for routine vaccination. If we reach 70-80 percent of vaccination coverage in girls aged 12-13 years, the reduction in cervical cancer in women aged 20-29 would reach 55-63 percent by 2025.
Vaccines are the most effective method of reducing disease morbidity and mortality throughout the world, along with water purification and wastewater treatment. Following the childhood vaccination schedule helps improve people's quality of life and, in general, contributes to increasing life expectancy.
However, although there are safe and effective vaccines capable of protecting the female population against genotypes 16 and 18, which cause 70 percent of cervical cancers, in Spain, for example, one in three girls does not receive the full three-dose vaccination schedule. In this sense, the main group for HPV vaccination are pre-adolescent girls before they have sex.
This vaccine plays the most active role in preventing the virus. A virus that, on the other hand, is very difficult to detect in time, since being a sexually transmitted virus, it enjoys a long latency period between infection and the appearance of symptoms, which complicates the detection of cancer in a early phase.
Marisol New. Editor of our site
You can read more articles similar to The Girls Vaccine, in the category of Vaccines on site.